Anakinra for rheumatoid arthritis - horizon scanning review

Record ID 32002000839
Authors' objectives:

To summarise the current research evidence on anakinra for rheumatoid arthritis (RA)

Authors' recomendations: - Clinical impact: Anakinra will become an additional option for patients with RA who do not respond to initial disease modifying antirheumatic drug (DMARD) therapy. - Service impact: Anakinra is likely to have little service impact as it is likely to be used alongside current treatments in people with moderate to severe disease. However, some patents prescribed anakinra will require help with administering injections. - Patient issues: There are unlikely to be significant patient issues raised from the introduction of anakinra for the treatment of RA, apart from the need for daily injections. - Financial and overall NHS impact: At this time the financial and overall impact are unclear but are may be significant if anakinra proves to be an effective treatment for the management of RA.
Authors' methods: Overview
Project Status: Completed
Year Published: 2001
URL for published report:
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England, United Kingdom
MeSH Terms
  • Antirheumatic Agents
  • Arthritis, Rheumatoid
Organisation Name: NIHR Horizon Scanning Centre
Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
Contact Email:
Copyright: National Horizon Scanning Centre
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.